News

Lialda is the first and only FDA-approved once-daily oral formulation of mesalamine. Shire will launch Lialda in the US in the first quarter of 2007. Once-daily Lialda with

Veno-occlusive disease (VOD) occurs when certain high dose chemotherapy and radiation therapies and stem cell transplantation damage cells of the blood vessels which results in a blockage of

The review period in Australia typically is 12 to 18 months from the date that the application is accepted. A marketing authorization application is also currently under review

The trial is designed to evaluate safety and clinical response rates in patients with rheumatoid arthritis. Small Modular ImmunoPharmaceutical (SMIP) drugs represent a novel class of immunotherapeutics that

China Biopharma owns 65% of the joint venture and its partner, Zhejiang Tianyuan Bio-Pharmaceutical, owns the remaining 35%. In June 2006, the Chinese government approved ZT Biotech for

Early versions of Novavax's HIV virus-like particle (VLP) vaccine were successful in triggering immune responses in preclinical studies. However, Novavax recently discovered a way to optimize the expression

Clinical trial supplies have been shipped, and patient recruitment has commenced for the trial of the drug, NE-180. The phase II trial is designed as an ascending dose

Phenoptin is being developed in partnership with BioMarin, for the treatment of patients with phenylketonuria (PKU), a rare genetic disorder where sufferers have a deficiency of an enzyme

The drug, MN-001, was well-tolerated but did not show a statistically significant clinical benefit compared to placebo on the primary endpoint at the doses tested in this trial.